glp-1 news today october 20 2025 Who Gets the Shot? Access by State Troubling Findings in Study of

N/DNo data

On the other hand, several preclinical trials have investigated the peptides effect on muscle mass, appetite, body weight, bone mass, and more: Increased Appetite, Muscle, and Body Weight: Laboratory studies have pointed out that ipamorelin may contribute to weight gain, associated with increases in both lean and fat mass

And as studies have proven, Zepbound is more effective than Wegovy in achieving weight loss, and only Zepbound is has been proven effective and approved by the FDA for treating sleep apnea in patients with obesity. The lawsuit seeks to restore coverage of Zepbound for people on CVS Caremark plans and award other appropriate equitable relief. CVS Caremark says the suit is without merit. Well defend ourselves vigorously against those claims, David Whitrap, vice president of external affairs for CVS Health, said in an email

A common misconception is that these medications are all intended to target weight loss, when in fact, some are meant to target blood sugar regulation in particular, and weight loss is more of a side effect that some people may experience, and others may not